|
medpundit |
||
 |
 |
|
Sunday, October 02, 2005Andrew Dillon, chief executive of Nice, said his institute was planning to speed up evaluation of new cancer drugs. "We have listened to what patients and healthcare professionals have told us about the need for timely advice on the use of new medicines, particularly for life-threatening conditions such as cancer," he said. “We have responded by proposing a new streamlined process for drugs, and we think these proposals can make a real difference.” Careful. That's what has gotten our FDA - and pharmaceutical companies - in so much trouble these past several years, rushing drugs into approval before adequately testing for side effects. posted by Sydney on 10/02/2005 08:40:00 AM 0 comments 0 Comments: |
|
